Jeremy M. Levin, D.Phil, MBBChirDr. Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, Inc. (NASDAQ: OVID) a publiccompany developing novel medicines for orphan and rare diseases of the brain. Dr. Levin has deep experience in the global biopharmaceuticals industry, leading companies and people to develop and commercialize medicines that address medical needs worldwide. He has been voted one of the 25 most influential people in the biopharmaceutical industry.
We have the capital, the expert team and the right strategy in place to unlock value in the rapidly growing field of rare neurology. With the perspectives of renowned biotech leaders who have recently joined our board and advisory team, we believe Ovid has the knowledge and access to pursue differentiated technologies and medicines for the brain.11 November 2021
Waiting increases the probability that the immunity gained by the original vaccination will diminish.11 November 2021
Greenwood’s leadership in the industry has allowed the United States to create a pro-innovation public policy environment that has become the envy of the world. Over the course of the next year-and-a-half that Greenwood will remain with BIO. The organization will continue to depend on his leadership as the industry fights short-sighted attempts to drain capital from our sector and curtail the intellectual property rights of innovators.16 August 2020